NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Zacks' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

10 equities research analysts have issued twelve-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' stock price to reach $37.75 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

Headlines about ITCI stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a decrease of 21.9% from the January 15th total of 8,370,000 shares. Based on an average daily volume of 2,790,000 shares, the short-interest ratio is currently 2.3 days. Approximately 14.0% of the shares of the company are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Geode Capital Management LLC (1.15%) and Rhenman & Partners Asset Management AB (0.90%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Geode Capital Management LLC, General American Investors Co. Inc. and Credit Suisse AG. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was bought by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates, Palo Alto Investors LP and TD Asset Management Inc.. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $24.46.

Intra-Cellular Therapies has a market capitalization of $1.36 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]